The company's lead candidate, OB-001, is a microbicide agent being developed as a contraceptive gel and an inhibitor of HIV transmission. Orion Biotechnology also has other candidates in the preclinical or discovery stage, such as OB-002H for HIV prevention, OB-002M for multiple sclerosis, and OB-002O for oncology. The company has partnerships with research institutions, including the Mintaka Research Foundation and the Center for Public Health Research at Nanjing University. In March 2018, Orion Biotechnology secured $5 million in financial funding.